Related Experiment Videos
Local injection therapy for hepatocellular carcinoma.
1Department of Ultrasound, Union Hospital of Fujian Medical University, Fuzhou 350001, China.
Hepatobiliary & Pancreatic Diseases International : HBPD INT
|February 17, 2006
Summary
Hepatocellular carcinoma (HCC) treatment faces limitations. Combining therapies may be essential for effectively treating HCC, especially larger tumors unresponsive to percutaneous ethanol injection.
Area of Science:
- Hepatology
- Oncology
- Minimally Invasive Therapies
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
- Curative treatments for early HCC include surgery, transplantation, and ablation, but have limitations.
- Resection is only suitable for 30% of patients with localized tumors and good hepatic reserve.
Purpose of the Study:
- To evaluate the effectiveness of local ablation therapies for Hepatocellular Carcinoma (HCC).
- To explore alternative treatments for unresectable HCC.
- To identify optimal treatment strategies for HCC based on tumor characteristics.
Main Methods:
- Percutaneous ethanol injection (PEI) is a minimally invasive local therapy for small HCC.
- Percutaneous hepatic quantified ethanol injection (PHQEI) and QESI (2-3 day intervals) show benefits for HCC patients.
- Evaluation of limitations of percutaneous methods for larger HCC nodules (>3 cm).
Main Results:
- PEI achieves an 80% complete response rate for HCC nodules smaller than 3 cm.
- Percutaneous methods have limitations for treating larger HCC nodules (>3 cm).
Conclusions:
- Local ablation therapy, like PEI, is effective for small HCC.
- Combined treatment approaches tailored to patient and tumor status are crucial for effective HCC management.